Policy | August 11, 2021
NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Subscribe To Our Newsletter & Stay Updated
